Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America

Judith SteinbergYára Dadalti FragosoJuan Carlos QuirozJuan Raul GarcíaCaroline GuerraVirginia Jiménez RodríguezClaudia RodríguezEthel CiampiEdgar Patricio Correa‐DíazMiguel Ángel Macías-Rodríguez2026-03-222026-03-22201910.1007/s40120-019-0139-yhttps://doi.org/10.1007/s40120-019-0139-yhttps://andeanlibrary.org/handle/123456789/45912Citaciones: 12enBiosimilarPharmacovigilanceLatin AmericansMedicineQuality (philosophy)Risk analysis (engineering)BusinessPractical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin Americaarticle